{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:23:35Z","timestamp":1782145415518,"version":"3.54.5"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a chronic, progressive neurodegenerative disorder characterized by heightened oxidative stress and persistent neuroinflammation. The sirtuin-1 (SIRT1) and nuclear factor erythroid 2\u2013related factor 2 (Nrf2) pathways play key roles in maintaining antioxidant defense, whereas activation of the NLRP3 inflammasome drives inflammation-mediated neuronal damage. However, their systemic alterations and interrelations in PD remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine and compare serum levels of SIRT1, Nrf2, and NLRP3 in patients with PD versus healthy controls and to analyze their correlations with fatigue severity and health-related quality of life indices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A case\u2013control study was conducted on 60 participants, including 30 patients diagnosed with idiopathic PD and 30 age- and sex-matched healthy controls. Serum SIRT1, Nrf2, and NLRP3 levels were quantified using enzyme-linked immunosorbent assay (ELISA). Disease impact and fatigue were assessed using the Parkinson\u2019s Disease Questionnaire-39 (PDQ-39) and Parkinson\u2019s Fatigue Scale-16 (PFS-16), respectively. Statistical analyses included between-group comparisons, Spearman correlations, multiple linear regression, and receiver operating characteristic (ROC) curve analysis. Multiple comparison corrections were applied to ensure robustness of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PD patients exhibited significantly lower SIRT1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.0009) and Nrf2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.0003) levels, and elevated NLRP3 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006). HRQoL and fatigue were markedly impaired in PD patients across all domains (PDQ-39 SI median 47.06 vs. 11.88; PFS-16 total median 3.93 vs. 2.07; all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01). SIRT1 and Nrf2 levels were negatively correlated with PDQ-39 and PFS-16 scores, while NLRP3 showed positive correlations. Multiple linear regression revealed that SIRT1, Nrf2, NLRP3, and disease duration were independent predictors of HRQoL and fatigue severity. ROC analyses demonstrated excellent diagnostic performance for SIRT1 (AUC\u202f=\u202f0.963) and high accuracy for Nrf2 (AUC\u202f=\u202f0.913) and NLRP3 (AUC\u202f=\u202f0.891).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PD is associated with impaired neuroprotection (SIRT1, Nrf2) and increased inflammation (NLRP3), which are closely linked to fatigue severity and diminished quality of life. These biomarkers independently predict clinical outcomes and show potential as minimally invasive diagnostic tools. Targeting oxidative stress and inflammasome-mediated inflammation may improve both molecular and clinical outcomes, highlighting the translational potential of the SIRT1\/Nrf2\/NLRP3 axis for personalized management of PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2025.1738871","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:19:12Z","timestamp":1768205952000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Interplay of oxidative stress and Inflammasome activation and clinical indices in Parkinson\u2019s disease: insights from serum SIRT1, Nrf2, and NLRP3 levels and PDQ-39\u2014a cross-sectional study"],"prefix":"10.3389","volume":"19","author":[{"given":"Khlood Mohammad","family":"Aldossary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa M.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amsha S.","family":"Alsegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alrubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wedad S.","family":"Sarawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"El-Khateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa","family":"Eltantawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen A.","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Elshorbagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohannad O.","family":"Khrieba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1497261","DOI":"10.3389\/fphar.2025.1497261","article-title":"Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson\u2019s disease","volume":"16","author":"AlRasheed","year":"2025","journal-title":"Front. Pharmacol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e18412","DOI":"10.1111\/jcmm.18412","article-title":"Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease","volume":"28","author":"Alrouji","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1434512","DOI":"10.3389\/fphar.2024.1434512","article-title":"The relation between Parkinson\u2019s disease and non-steroidal anti-inflammatories; a systematic review and meta-analysis","volume":"15","author":"Badawoud","year":"2024","journal-title":"Front. Pharmacol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10787-022-01125-5","article-title":"SIRT1 pathway in Parkinson\u2019s disease: a faraway snapshot but so close","volume":"31","author":"Batiha","year":"2023","journal-title":"Inflammopharmacology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson's disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/cdd.2015.96","article-title":"Sirtuin 1 suppresses mitochondrial dysfunction of ischemic mouse livers in a mitofusin 2-dependent manner","volume":"23","author":"Biel","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.parkreldis.2004.07.007","article-title":"The Parkinson fatigue scale","volume":"11","author":"Brown","year":"2005","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3892\/etm.2017.5400","article-title":"Resveratrol attenuates type 2 diabetes mellitus by mediating mitochondrial biogenesis and lipid metabolism via Sirtuin type 1","volume":"15","author":"Cao","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s12640-021-00392-4","article-title":"SIRT1 protects dopaminergic neurons in Parkinson\u2019s disease models via PGC-1\u03b1-mediated mitochondrial biogenesis","volume":"39","author":"Chen","year":"2021","journal-title":"Neurotox. Res."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"10809","DOI":"10.3390\/ijms241310809","article-title":"Unraveling molecular and genetic insights into neurodegenerative diseases: advances in understanding Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s diseases and amyotrophic lateral sclerosis","volume":"24","author":"Ciurea","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e55375","DOI":"10.1371\/journal.pone.0055375","article-title":"Triggering of inflammasome by aggregated \u03b1\u2013synuclein, an inflammatory response in synucleinopathies","volume":"8","author":"Codolo","year":"2013","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3892\/ijmm.2016.2503","article-title":"SIRT1 exerts protective effects against paraquat-induced injury in mouse type II alveolar epithelial cells by deacetylating NRF2 in vitro","volume":"37","author":"Ding","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"738686","DOI":"10.3389\/fnagi.2021.738686","article-title":"Relieving cellular energy stress in aging, neurodegenerative, and metabolic diseases, SIRT1 as a therapeutic and promising node","volume":"13","author":"Fang","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"729757","DOI":"10.3389\/fnins.2021.729757","article-title":"Oxidative stress and cognitive decline: the neuroprotective role of natural antioxidants","volume":"15","author":"Franzoni","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5772\/intechopen.102319","article-title":"Status: role of Nrf2, a master regulator of cellular redox","volume":"2","author":"Gambhir","year":"2022","journal-title":"Reactive Oxygen Species"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e70213","DOI":"10.1002\/iid3.70213","article-title":"Molecular mechanism of NLRP3 inflammasome in inflammatory diseases and tumors","volume":"13","author":"Gong","year":"2025","journal-title":"Immunity Inflammat. Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/mds.27874","article-title":"Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease","volume":"35","author":"Haque","year":"2020","journal-title":"Mov. Disord."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10238-025-01759-z","article-title":"SIRT1 as a masterful reciprocal regulator of molecular mechanisms and signaling pathways involved in tumor growth and expansion","volume":"25","author":"Hashemi","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e0262796","DOI":"10.1371\/journal.pone.0262796","article-title":"Effects of rasagiline on Parkinson\u2019s disease questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson\u2019s disease: a post-hoc analysis of clinical trials in Japan","volume":"17","author":"Hattori","year":"2022","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/jcp.27200","article-title":"Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease","volume":"234","author":"He","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.yexcr.2017.09.042","article-title":"The crosstalk between Sirt1 and Keap1\/Nrf2\/ARE anti-oxidative pathway forms a positive feedback loop to inhibit FN and TGF-\u03b21 expressions in rat glomerular mesangial cells","volume":"361","author":"Huang","year":"2017","journal-title":"Exp. Cell Res."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"15811","DOI":"10.1523\/JNEUROSCI.4088-10.2010","article-title":"The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18","volume":"30","author":"Jha","year":"2010","journal-title":"J. Neurosci."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.14260\/jemds\/2021\/404","article-title":"Impact of motor and non-motor symptoms on quality of life in Parkinson\u2019s disease-a questionnaire based observational study from Karad, India","volume":"10","author":"Kandharkar","year":"2021","journal-title":"J. Evol. Med. Dent. Sci."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41418-018-0124-5","article-title":"MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration","volume":"26","author":"Lee","year":"2019","journal-title":"Cell Death Different."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.14336\/AD.2020.0216","article-title":"The critical role of SIRT1 in Parkinson\u2019s disease: mechanism and therapeutic considerations","volume":"11","author":"Li","year":"2020","journal-title":"Aging Dis."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ctim.2016.09.008","article-title":"Multi-dimensional analysis on Parkinson\u2019s disease questionnaire-39 in Parkinson\u2019s patients treated with Bushen Huoxue granule: a multicenter, randomized, double-blinded and placebo controlled trial","volume":"29","author":"Li","year":"2016","journal-title":"Complement. Ther. Med."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"107595","DOI":"10.1016\/j.clineuro.2023.107595","article-title":"Serum Sirtuin1 level decreases in Parkinson's disease and vascular parkinsonism: a prospective observational study","volume":"225","author":"Li","year":"2023","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"pyw047","DOI":"10.1093\/ijnp\/pyw047","article-title":"Metformin prevents dopaminergic neuron death in MPTP\/P-induced mouse model of Parkinson\u2019s disease via autophagy and mitochondrial ROS clearance","volume":"19","author":"Lu","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.2147\/JIR.S478683","article-title":"Nrf2 deficiency exacerbates Parkinson\u2019s disease by aggravating NLRP3 Inflammasome activation in MPTP-induced mouse models and LPS-induced BV2 cells","volume":"17","author":"Lu","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3389\/fphys.2019.01173","article-title":"The role of Sirtuin1 in regulating endothelial function, arterial remodeling and vascular aging","volume":"10","author":"Man","year":"2019","journal-title":"Front. Physiol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejphar.2017.02.005","article-title":"Protective effect of Nrf2\u2013ARE activator isolated from green perilla leaves on dopaminergic neuronal loss in a Parkinson's disease model","volume":"798","author":"Masaki","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1437939","DOI":"10.3389\/fphar.2024.1437939","article-title":"Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications","volume":"15","author":"Mayer","year":"2024","journal-title":"Front. Pharmacol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mdc3.13523","article-title":"Age cutoff for early-onset Parkinson's disease: recommendations from the International Parkinson and Movement Disorder Society task force on early onset Parkinson's disease","volume":"9","author":"Mehanna","year":"2022","journal-title":"Mov. Disord. Clinic. Pract."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3390\/antiox11122345","article-title":"Nrf2 and oxidative stress: a general overview of mechanisms and implications in human disease","volume":"11","author":"Ngo","year":"2022","journal-title":"Antioxidants"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"21745","DOI":"10.1074\/jbc.M602909200","article-title":"Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction","volume":"281","author":"Qin","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"787258","DOI":"10.3389\/fncel.2021.787258","article-title":"A perspective on Nrf2 signaling pathway for neuroinflammation: a potential therapeutic target in Alzheimer's and Parkinson's diseases","volume":"15","author":"Saha","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e0266140","DOI":"10.1371\/journal.pone.0266140","article-title":"Measuring quality of life with the Parkinson\u2019s disease Questionnaire-39 in people with cognitive impairment","volume":"17","author":"Sch\u00f6nenberg","year":"2022","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1007\/s00415-022-11491-3","article-title":"Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson\u2019s disease: mechanisms and therapeutic implications","volume":"270","author":"Soraci","year":"2023","journal-title":"J. Neurol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12868-021-00687-4","article-title":"Increased expression of pathological markers in Parkinson\u2019s disease dementia post-mortem brains compared to dementia with Lewy bodies","volume":"23","author":"Tu","year":"2022","journal-title":"BMC Neurosci."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12640-024-00716-0","article-title":"Blunted melatonin circadian rhythm in Parkinson\u2019s disease: express bewilderment","volume":"42","author":"Turkistani","year":"2024","journal-title":"Neurotox. Res."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12881-014-0131-4","article-title":"Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson\u2019s disease\u2013a multicenter study","volume":"15","author":"von Otter","year":"2014","journal-title":"BMC Med. Genet."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"757161","DOI":"10.3389\/fphar.2021.757161","article-title":"Pharmacological modulation of Nrf2\/HO-1 signaling pathway as a therapeutic target of Parkinson\u2019s disease","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.intimp.2018.12.019","article-title":"The mechanisms of NLRP3 inflammasome\/pyroptosis activation and their role in Parkinson's disease","volume":"67","author":"Wang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"16210","DOI":"10.3390\/ijms242216210","article-title":"The role of sirtuin-1 (SIRT1) in the physiology and pathophysiology of the human placenta","volume":"24","author":"W\u0105troba","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"831168","DOI":"10.3389\/fimmu.2022.831168","article-title":"Regulation of SIRT1 and its roles in inflammation","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e28838","DOI":"10.1016\/j.heliyon.2024.e28838","article-title":"Role of NLRP3 in Parkinson's disease: specific activation especially in dopaminergic neurons","volume":"10","author":"Yu","year":"2024","journal-title":"Heliyon"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1007\/s11033-023-08409-1","article-title":"Targeting Nrf2 signaling pathway and oxidative stress by resveratrol for Parkinson\u2019s disease: an overview and update on new developments","volume":"50","author":"Zamanian","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"pyv006","DOI":"10.1093\/ijnp\/pyv006","article-title":"NLRP3 inflammasome mediates chronic mild stress-induced depression in mice via neuroinflammation","volume":"18","author":"Zhang","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s10143-020-01387-z","article-title":"NLRP3 inflammasomes are involved in the progression of postoperative cognitive dysfunction: from mechanism to treatment","volume":"44","author":"Zhao","year":"2021","journal-title":"Neurosurg. Rev."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mds.22875","article-title":"Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times","volume":"25","author":"Zhao","year":"2010","journal-title":"Mov. Disord."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e464","DOI":"10.1016\/S2666-7568(24)00094-1","article-title":"Temporal trends in the prevalence of Parkinson's disease from 1980 to 2023: a systematic review and meta-analysis","volume":"5","author":"Zhu","year":"2024","journal-title":"Lancet Healthy Longev."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s10072-020-04711-z","article-title":"Reduced serum SIRT1 levels in patients with Parkinson\u2019s disease: a cross-sectional study in China","volume":"42","author":"Zhu","year":"2021","journal-title":"Neurol. Sci."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2025.1738871\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:19:13Z","timestamp":1768205953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2025.1738871\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":55,"alternative-id":["10.3389\/fnins.2025.1738871"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2025.1738871","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1738871"}}